Breaking News
November 14, 2018 - Researchers to develop sports-specific classification system for blind football
November 14, 2018 - Preschool children show awake responses to naptime nonsense words
November 14, 2018 - Survey shows negative effect of vulvovaginal atrophy symptoms on quality of life for women
November 14, 2018 - Study sheds light on mechanisms that prevent autoimmune attack
November 14, 2018 - Sleep quality found to be worse for women who undergo surgical menopause
November 14, 2018 - New study provides deeper insight into chromosome segregation during mitosis
November 14, 2018 - Appendix removal is linked to lower risk of Parkinson’s
November 14, 2018 - Lifting weights for less than an hour a week may reduce cardiovascular disease risk
November 14, 2018 - Pulmonary rehabilitation rarely received by hospitalized COPD patients despite health benefits
November 14, 2018 - New anti-HER2 drug shows promising anti-tumor activity in gullet, stomach and bowel cancers
November 14, 2018 - Regular head circumference assessment of preterm babies can help identify long-term IQ problems
November 14, 2018 - Brigham investigators examine opioid use among Massachusetts adolescents, prescription trends
November 14, 2018 - Study defines biomarker in response to treatment of castration-resistant prostate cancer
November 14, 2018 - Study identifies potential therapeutic strategy for patients with clear cell renal cancer
November 14, 2018 - Bausch Health Announces U.S. Launch of Bryhali (halobetasol propionate) Lotion, 0.01%, for Plaque Psoriasis In Adults
November 14, 2018 - Alpha Fetoprotein (AFP) Tumor Marker Test: MedlinePlus Lab Test Information
November 14, 2018 - Researchers evaluate controversial treatment for Parkinson’s disease psychosis
November 14, 2018 - AI could help veterinarians code their notes
November 14, 2018 - Pre-schoolers with autism thrive in mainstream classroom settings
November 14, 2018 - Individual and work-related factors may help promote hospital physician engagement, finds study
November 14, 2018 - Complementary and alternative medicine is widely used by general population in England
November 14, 2018 - Study reveals link between tobacco availability and smoking during pregnancy
November 14, 2018 - Purdue researchers develop translucent base for silicon patches to deliver exact doses of biomolecules
November 14, 2018 - New technology based on moths and magnets could help treat genetic diseases
November 14, 2018 - Concussion-Related Biomarkers Vary Based on Sex, Race
November 14, 2018 - One more year of high school may shape waistlines later in life
November 14, 2018 - Dissecting high drug costs – Scope
November 14, 2018 - Study shows novel strategy to reduce breast cancer bone metastasis
November 14, 2018 - Empowering the NHS through Industry Partnerships
November 14, 2018 - One size does not fit all in obesity treatment, study finds
November 14, 2018 - Seeking ways to prevent ‘secondary cataracts’
November 14, 2018 - Change Within the Eye May Be Early Warning for Macular Degeneration
November 14, 2018 - Study of 500,000 people clarifies the risks of obesity
November 14, 2018 - Ultrasound releases drug to alter activity in targeted brain areas in rats | News Center
November 14, 2018 - Umass Amherst researchers battle against youth suicide in rural Alaska Native communities
November 14, 2018 - Cancer stem cells depend on amino acid metabolism, and it’s proving to be their Achilles’ heel
November 14, 2018 - Epigenetic link found between prenatal exposure to maternal smoking and offspring’s cardio-metabolic health
November 14, 2018 - Meditation, music may change biomarkers of cellular aging and Alzheimer’s disease in older adults
November 14, 2018 - Multidisciplinaryresearch teams selected to study age-related brain disorders
November 14, 2018 - The Current issue of “The view from here” is concerned with Informatics
November 14, 2018 - Researchers identify tool to help transgender women have a more authentic voice
November 14, 2018 - Four faculty members appointed to endowed professorships | News Center
November 13, 2018 - Research finds strongest evidence yet that obesity causes depression
November 13, 2018 - Researchers compare stools of breastfed and formula-fed infants
November 13, 2018 - Entasis Therapeutics Announces Zoliflodacin Phase 2 Results Published in The New England Journal of Medicine
November 13, 2018 - Gene changes driving myopia reveal new focus for drug development
November 13, 2018 - $6 million grant to support study of preeclampsia, atherosclerosis links | News Center
November 13, 2018 - Beneficial gut microbes metabolize high-fiber diet to improve heart health in mouse model
November 13, 2018 - Excessive use of social media through visual postings linked to increase in narcissistic traits
November 13, 2018 - Study finds why obesity both fuels cancer growth and helps immunotherapy to kill tumors
November 13, 2018 - Women prefer and invest more in daughters, while men favor sons
November 13, 2018 - With hospitalization losing favor, judges order outpatient mental health treatment
November 13, 2018 - Transgenic rat model may provide new insights into cerebral amyloid angiopathy
November 13, 2018 - Study identifies factors tied to greater risk of advanced liver disease in cystic fibrosis patients
November 13, 2018 - Risk of blindness among premature babies with low levels of blood platelets
November 13, 2018 - A new strategy for combatting antibiotic-resistant infections
November 13, 2018 - Study aims to find which outreach method is more effective at improving cancer screening rates
November 13, 2018 - Insufficient sleep duration linked with unhealthy lifestyle profile among children
November 13, 2018 - IIASA researchers introduce new, simple measure for human wellbeing
November 13, 2018 - Magnetic nanosprings used as targeted drug delivery agents for anticancer therapy
November 13, 2018 - Scientists examine FCMs containing silver nanoparticles
November 13, 2018 - Failed DNA repair triggers chromosomal chaos
November 13, 2018 - Study shows new emerging role of osteopontin in HCV-related hepatocellular carcinoma
November 13, 2018 - Food insecurity during pregnancy linked to severity of neonatal abstinence syndrome
November 13, 2018 - Majority of Americans are concerned about health threat posed by antibiotic resistance
November 13, 2018 - Addition of Elotuzumab Ups PFS in Refractory Multiple Myeloma
November 13, 2018 - Study finds women with pregnancy-related nausea, vomiting use marijuana more
November 13, 2018 - Lethal heart rhythm more likely to be found in patients with common heart failure
November 13, 2018 - Study provides new clues to origin and development of multiple sclerosis
November 13, 2018 - Climate change could pose threat to male fertility
November 13, 2018 - Researchers discover how mitochondria deploy a powerful punch against disease-causing bacteria
November 13, 2018 - AHA: Traumatic Childhood Could Increase Heart Disease Risk in Adulthood
November 13, 2018 - Feeling the Burn? | NIH News in Health
November 13, 2018 - Women’s birth canals in Kenya, Korea, Kansas not the same: study
November 13, 2018 - Fecal microbiota transplantation effective against ICI-associated colitis
November 13, 2018 - New physical activity guidelines released that urge people to “move more”
November 13, 2018 - Angiotensin receptor blockers improve sodium excretion in blacks
November 13, 2018 - New project seeks to address alarming injury rate in youth footballers
November 13, 2018 - Fish oil or omega 3 fatty acid supplements can prevent heart attacks finds study
November 13, 2018 - The Human Heart-in-a-Jar That Could One Day Replace Animal Testing
Breast cancer survival could be extended with two new drug combinations

Breast cancer survival could be extended with two new drug combinations

image_pdfDownload PDFimage_print

Study 1

A new study has shown that a combination of drugs palbociclib, along with hormone therapy can significantly increase the survival among women with advanced breast cancer.

The new study titled, “Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer,” was published in the latest issue of the New England Journal of Medicine and the results of the PALOMA-3 trial were also presented at the European Society of Medical Oncology congress in Munich, Germany. The researchers from Institute of Cancer Research and Royal Marsden NHS Foundation Trust, found that women with advanced breast cancer treated with this combination lived for seven months longer than those who were treated with hormonal therapy alone. Among women who had earlier responded favourably to hormone therapy, the average survival when palbociclib and hormone therapy was administered together was around 10 months.

Dividing breast cancer cell. Image Credit: royaltystockphoto.com / Shutterstock

Dividing breast cancer cell. Image Credit: royaltystockphoto.com / Shutterstock

Study leader, Professor Nick Turner of the Institute of Cancer Research said, “These results indicate that we can now offer women with incurable breast cancer some precious extra survival time before their condition worsens. It is very encouraging.” The study involved a total of 521 women with advanced, hormone-sensitive breast cancer. The researchers attempted to see if the combination therapy worked better than conventional chemotherapy.

Results of the study funded by palbociclib’s manufacturer Pfizer, showed that women who were given a combination therapy survived for an average of 34.9 months. This is an average of 6.9 months longer than women treated only with hormonal therapy. Three years after the study enrolment 49.6 percent of the participants who had received the combination therapy were still alive compared to 40.8 percent of the participants who had received only hormone therapy.

Authors concluded in their study, “Among patients with hormone-receptor–positive, HER2-negative advanced breast cancer who had sensitivity to previous endocrine therapy, treatment with palbociclib–fulvestrant resulted in longer overall survival than treatment with placebo–fulvestrant. The differences in overall survival in the entire trial group were not significant.”

Study 2

Yet another combination of an immunotherapy drug atezolizumab with standard chemotherapy was found to prolong life of patients with advanced triple-negative breast cancers.

This study titled, “Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer,” was led by Professor Peter Schmid, clinical director of breast cancer at St Bartholomew’s Hospital and professor of cancer medicine at Queen Mary University of London and the results of the study were published in the New England Journal of Medicine. According to Schmid this study is a “massive step forward” and could soon “lead to a cure in some patients and may apply in the treatment of other forms of breast cancers in the future.”

The researchers explained that the chemotherapy made the tumour vulnerable and the immunotherapy then targeted the breast cancer cells. In this trial 451 patients were included in two groups – one to receive atezolizumab plus nab-paclitaxel or placebo plus nab-paclitaxel. The patients all had untreated metastatic triple-negative breast cancer. The patients were all followed up for an average 12.9 months.

Results showed that progression-free survival was 7.2 months with atezolizumab plus nab-paclitaxel and it was 5.5 months with placebo plus nab-paclitaxel. Median overall survival was 21.3 months with the combination therapy and it was 17.6 months with paclitaxel along with placebo. Side effects were seen among 15.9 percent patients on the combination and 8.2 percent on paclitaxel alone. At 25 months after the study 60 percent of the combination group were still alive. The combination treatment was found to reduce the risk of the cancer progress by up to 40 percent.

According to Professor Schmid, “Triple-negative breast cancer is an aggressive form of breast cancer. It is particularly tragic that those affected are often young. I’m thrilled that by using a combination of immunotherapy and chemotherapy we are able to significantly extend lives compared to the standard treatment of chemotherapy alone.”

Source:

https://www.nejm.org/doi/full/10.1056/NEJMoa1810527 and https://www.nejm.org/doi/full/10.1056/NEJMoa1809615

Tagged with:

About author

Related Articles